Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EPS (Weighted Average and Diluted) (2016 - 2025)

Mimedx (MDXG) has disclosed EPS (Weighted Average and Diluted) for 14 consecutive years, with $0.1 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 100.0% to $0.1 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.32 through Dec 2025, up 14.29% year-over-year, with the annual reading at $0.32 for FY2025, 14.29% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.1 in Q4 2025 for Mimedx, down from $0.11 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.28 in Q4 2023 to a low of -$0.11 in Q1 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.03 across 5 years, with a median of $0.05 in 2024.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 652.56% in 2022; the steepest drop was 266.67% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.01 in 2021, then soared by 652.56% to $0.07 in 2022, then skyrocketed by 300.0% to $0.28 in 2023, then crashed by 82.14% to $0.05 in 2024, then surged by 100.0% to $0.1 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MDXG at $0.1 in Q4 2025, $0.11 in Q3 2025, and $0.06 in Q2 2025.